LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous lymphoid malignancy with poor outcomes for refractory patients.
• Current understanding of immune checkpoint mechanisms in DLBCL treatment is limited.
• This study investigates the roles of PD1 and LAG3 in CD8+ T cells during DLBCL therapy.

Purpose of the Study:

• To explore the therapeutic potential of programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 (LAG3) in CD8+ T cells for Diffuse large B-cell lymphoma (DLBCL).
• To elucidate the mechanisms underlying immune checkpoint involvement in DLBCL treatment.

Main Methods:

• Flow cytometry was used to analyze T cell populations, cytokine levels, and PD1/LAG3 expression in DLBCL patients and healthy controls.
• Cytokine levels in CD8+ T cells from DLBCL patients were compared before and after treatment, with and without PD1/LAG3 blockade.

Main Results:

• Post-treatment, DLBCL patients showed increased CD4+ and CD8+ T cell proportions and cytokine levels approaching those of healthy controls.
• Expression of PD1, LAG3, and combined PD1/LAG3 was lower on T cells after treatment compared to untreated patients.
• Blocking PD1 and LAG3 in CD8+ T cells significantly reduced cytokine production.

Conclusions:

• PD1 and LAG3 expressed on CD8+ T cells are potential therapeutic targets in DLBCL.
• Targeting PD1 and LAG3 may play a significant role in the treatment of DLBCL patients.